[HTML][HTML] Efficacy and safety of molnupiravir for COVID-19 patients
The Coronavirus Disease 2019 (COVID-19) continues to be a major source of morbidity and
mortality across the globe. Current medical therapy against COVID-19 includes drugs that …
mortality across the globe. Current medical therapy against COVID-19 includes drugs that …
Real-world effectiveness of molnupiravir and nirmatrelvir/ritonavir among COVID-19 inpatients during Hong Kong's Omicron BA. 2 wave: an observational study
Background Real-world evidence on the effectiveness of oral antivirals in mild-to-moderate
COVID-19 patients is urgently needed. This retrospective cohort study aims to evaluate the …
COVID-19 patients is urgently needed. This retrospective cohort study aims to evaluate the …
Drug repurposing and observational studies: the case of antivirals for the treatment of COVID-19
MA Hernán, J Del Amo - Annals of Internal Medicine, 2023 - acpjournals.org
Remdesivir and molnupiravir were the only 2 repurposed antivirals that were approved for
emergency use during the COVID-19 pandemic. Both drugs received their emergency use …
emergency use during the COVID-19 pandemic. Both drugs received their emergency use …
COVID-19 sequelae: can long-term effects be predicted?
E Gavriilaki, S Kokoris - The Lancet Infectious Diseases, 2022 - thelancet.com
The COVID-19 pandemic has had an unprecedented impact on all aspects of human activity
worldwide. 1 Despite the positive effect that vaccination, anti-viral treatment, and monoclonal …
worldwide. 1 Despite the positive effect that vaccination, anti-viral treatment, and monoclonal …
COVID-19 therapeutics
Since the emergence of COVID-19 in 2020, an unprecedented range of therapeutic options
has been studied and deployed. Healthcare providers have multiple treatment approaches …
has been studied and deployed. Healthcare providers have multiple treatment approaches …
Factors Influencing COVID‐19 Risk: Insights From Molnupiravir Exposure‐Response Modeling of Clinical Outcomes
Molnupiravir (MOV) is an oral antiviral for the treatment of coronavirus disease 2019 (COVID‐
19) in outpatient settings. This analysis investigated the relationship between β‐D‐N4 …
19) in outpatient settings. This analysis investigated the relationship between β‐D‐N4 …
Why molnupiravir fails in hospitalized patients
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of
coronavirus disease 2019 (COVID-19), has radically altered daily life. Effective antiviral …
coronavirus disease 2019 (COVID-19), has radically altered daily life. Effective antiviral …
Molnupiravir Outpatient Treatment for Adults with COVID-19 in a Real-World Setting—A Single Center Experience
K Czarnecka, P Czarnecka, O Tronina… - Journal of Clinical …, 2022 - mdpi.com
Background: Molnupiravir is approved for the treatment of adult patients with mild to
moderate COVID-19. The main goal of the treatment is to reduce hospitalization and …
moderate COVID-19. The main goal of the treatment is to reduce hospitalization and …
Camostat Mesylate Versus Lopinavir/Ritonavir in Hospitalized Patients with COVID-19—Results From a Randomized, Controlled, Open Label, Platform Trial …
M Karolyi, E Pawelka, S Omid, F Koenig… - Frontiers in …, 2022 - frontiersin.org
Background: To date, no oral antiviral drug has proven to be beneficial in hospitalized
patients with COVID-19. Methods: In this randomized, controlled, open-label, platform trial …
patients with COVID-19. Methods: In this randomized, controlled, open-label, platform trial …
Tenofovir disoproxil fumarate/emtricitabine and severity of coronavirus disease 2019 in people with HIV infection
J Del Amo, R Polo, S Moreno, E Martínez, A Cabello… - Aids, 2022 - journals.lww.com
Background: Effective, safe, and affordable antivirals are needed for coronavirus disease
2019 (COVID-19). Several lines of research suggest that tenofovir may be effective against …
2019 (COVID-19). Several lines of research suggest that tenofovir may be effective against …